

Drug Name	Generic Drug Name	Indication	Application Status	Date Application Approved
Lucentis	ranibizumab	neovascular age-related macular degeneration (AMD) as per the Novartis Pharmaceuticals Australia Pty Ltd protocol	APPROVED	27/11/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	2/07/2012
Cholecystokinin		for imaging of the biliary tract	APPROVED	12/09/2011
cholecystokinin	Kinevac/ Sincalide	imaging of the biliary tract	APPROVED	12/09/2011
cholecystokinin	Kinevac/ Sincalide	for use in nuclear medicine biliary studies	APPROVED	12/09/2011
Melatonin		sleep disturbance in children with severe disabilities	APPROVED	25/08/2011
Indocyanine Green		retinal angiography	APPROVED	13/09/2011
Cholecystokinin	Sincalide, Kinevac	for imaging of the biliary tract.	APPROVED	13/09/2011
cholecystekinin	Kinevac/ Sincalide	use in imaging of the biliary tract	APPROVED	13/09/2011
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	12/09/2011
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography.	APPROVED	12/09/2011
Indocyanine Green		during vitreo-retinal suegery and for intravenous injection to perform ICG angiography	APPROVED	12/09/2011
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography.	APPROVED	8/11/2011
Cholecystokinin	Sincalide, Kinevac	for nuclear medicine biliary studies.	APPROVED	14/11/2011
Mafenide 5%	Sulfamylon	for wound management of deep partial and full thickness burns to ears	APPROVED	13/09/2011
Mifepristone		To decrease the length of labour induction in cases of foetal anomalies, foetal death in utero or severe maternal illness in first and mid trimester of pregnancy	APPROVED	30/08/2011
Mifepristone		To decrease the length of labour induction in cases of foetal anomalies, foetal death in utero or severe maternal illness in first and mid trimester of pregnancy	APPROVED	30/08/2011
Mifepristone		To decrease the length of labour induction in cases of foetal anomalies, foetal death in utero or severe maternal illness in first and mid trimester of pregnancy	APPROVED	30/08/2011
Mifepristone		To decrease the length of labour induction in cases of foetal anomalies, foetal death in utero or severe maternal illness in first and mid trimester of pregnancy	APPROVED	30/08/2011
Mifepristone		To decrease the length of labour induction in cases of foetal anomalies, foetal death in utero or severe maternal illness in first and mid trimester of pregnancy	APPROVED	30/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011

Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergies	APPROVED	12/02/2013
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	9/11/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	9/11/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	9/11/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	9/11/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	9/11/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	9/11/2011
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012

Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		Termination of pregnancy when used strictly in accordance with NSW Health policy directives and RWH guidelines.	APPROVED	11/05/2012
Mifepristone		for medical abortion in first trimester	APPROVED	3/02/2012
cholecystokinin	Kinevac/ Sincalide	for assessment of gall bladder function in patients with suspected chronic acalculous cholecystitis	APPROVED	8/11/2011
cholecalciferol 1.25mg (50,000iu)		for the treatment of moderate to severe Vitamin D deficiency	APPROVED	27/10/2011
cholecalciferol 1.25mg (50,000iu)		for the treatment of moderate to severe Vitamin D deficiency	APPROVED	27/10/2011
cholecalciferol 1.25mg (50,000iu)	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	27/10/2011
Multiple Allergen Skin Test Reagents (Greer Laboratories U.S.A)		Allergy skin test reagents are to be used in patients to assist in the diagnosis of life threatening allergic reactions	APPROVED	24/01/2012
cholecalciferol 1.25mg (50,000iu)		for the treatment of moderate to severe Vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol 50,000 iu	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol 50,000 iu	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	7/11/2011
Cholecalciferol 100,000 units i.m. injection	D3- Vicotrat	for treatment of vitamin D deficiency and malabsorption	APPROVED	28/02/2012
Dydrogesterone (Duphaston) 10mg tablets	Duphaston	for short term treatment of oestrogen deficiency symptoms in women with an intact uterus	APPROVED	6/08/2012
Multiple Allergen Skin Test Reagents (Stallergenes/Alvostal)		for skin prick testing for allergy assessment	APPROVED	31/07/2012
Multiple Allergen Skin Test Reagents (Hollister-Stierl)		for skin prick testing for allergy assessment	APPROVED	31/07/2012
cholecalciferol		for treatment of moderate to severe Vitamin D deficiency	APPROVED	20/07/2012
cholecalciferol		for treatment of moderate to severe Vitamin D deficiency	APPROVED	20/07/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	20/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Cantharone	Cantharidin	warts molluscum contagiosum	APPROVED	29/11/2011
Celiprolol Hydrochloride 200mg Tablets		Vascular Ehlers Danlos (EDS)	APPROVED	10/01/2012

Celiprolol Hydrochloride 200mg Tablets		Vascular Ehlers Danlos (EDS)	APPROVED	10/01/2012
Celiprolol Hydrochloride 200mg Tablets		Vascular Ehlers Danlos (EDS)	APPROVED	10/01/2012
Indocyanine Green		during retinal angiography	APPROVED	28/11/2011
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	29/11/2011
Lorazepam Injections		acute arousal and agitation in patients with psychosis	APPROVED	29/11/2011
pyrazinamide		treatment of tuberculosis	APPROVED	28/11/2011
Multiple Allergen Skin Test Reagents		skin prick testing for allergies to inhaled and ingested allergens	APPROVED	6/02/2012
Mifepristone		Midtrimester termination of pregnancy	APPROVED	11/05/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergy testing.	APPROVED	20/03/2012
cholecalciferol 1.25mg (50,000IU)	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	18/12/2012
cholecalciferol 1.25mg (50,000 IU)	Cal D Forte, D-3-50	moderate to severe vitamin D deficiency	APPROVED	18/12/2012
cholecalciferol 1.25mg (50,000 IU)	Cal D Forte, D-3-50	moderate to severe vitamin D deficiency	APPROVED	18/12/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	19/12/2012
Mifepristone		Medical abortion in 1st and 2nd trimester (foetal abnormalities, serious/life threatening condition)..Cervical Priming prior to surgical abortion in the 1st and 2nd trimesters	APPROVED	21/12/2012
Mifepristone		Medical abortion in 1st and 2nd trimester (foetal abnormalities, serious/life threatening condition)..Cervical Priming prior to surgical abortion in the 1st and 2nd trimesters	APPROVED	21/12/2012
Mifepristone		for medical abortion in first trimester (up to 63 days), medical abortion in 2nd trimester, cervical priming prior to surgical abortion (12-15 weeks gestation)	APPROVED	23/05/2012
Cyclopentolate 0.2% Phenylephrine 1%	Cyclomydril	pupil dilation	APPROVED	30/05/2012
Mifepristone		for medical abortion in first trimester (up to 63 days)	APPROVED	11/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
cholecalciferol		vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	29/06/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	29/06/2012
DAP-kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for skin prick and intradermal allergy testing for investigation of beta-lactam/penicillin	APPROVED	23/05/2012

Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	8/11/2011
Mifepristone		for medical abortion in first trimester	APPROVED	3/09/2012
Cyclosporin Eye Drops	Restasis	Severe inflammatory external eye disease causing dry eye,	APPROVED	20/04/2012
Methacholine		asthma challenge (bronchoprovocation) testing	APPROVED	20/04/2012
Multiple Allergens (full range)	Alyostal Skin testing reagents	skin prick testing for allergies	APPROVED	23/05/2012
DAP-kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for skin prick and intradermal allergy testing for investigation of beta-lactam/penicillin	APPROVED	23/05/2012
DAP-kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for skin prick and intradermal allergy testing for investigation of beta-lactam/penicillin	APPROVED	23/05/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	3/08/2011
Fosfomycin tromethamine		for treatment of lower urinary tract infections caused by multi-drug resistant gram negative organisms (ESBL)	APPROVED	6/06/2012
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Indocyanine Green		for use during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	18/07/2011
Penicillin Allergenic Determinants (PAD)		Diagnosis of penicillin allergic reactions	APPROVED	18/07/2011
Triamcinolone Hexacetonide		for intra-articular injection in children with inflammatory arthritis	APPROVED	6/09/2011
Multiple Allergen Skin Test Reagents (Alyostal)		Allergy Testing - skin prick test	APPROVED	18/07/2011
ALK-Abello Skin Prick Testing Reagents		Allergy Testing - skin prick test	APPROVED	18/07/2011
Diater DA Skin Prick Testing Reagents		Allergy Testing - skin prick test	APPROVED	18/07/2011
Multiple Allergen Skin Test Reagents	Alyostal	for skin prick testing for allergies	APPROVED	19/07/2011
ALK-Abello Skin Prick Testing Reagents		Skin prick testing for diagnostic allergy testing	APPROVED	19/07/2011
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing in allergy testing	APPROVED	19/07/2011
ALK-Abello Skin prick testing reagents		for skin prick testing in allergy testing	APPROVED	19/07/2011
Pipothiazine palmitate (Piportil) depot injection	Piportil	treatment of psychosis when the patient has intolerable side effect to other depot injections	APPROVED	8/08/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	19/07/2011

[illegible]

Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Mifepristone		For the management of pregnancy loss and medical termination of pregnancy	APPROVED	8/07/2011
Multiple Allergen Skin Test Reagents (Alk-Abello)		skin prick testing for for allergies	APPROVED	18/07/2011
Multiple Allergen Skin Test Reagents		skin prick testing for allergies	APPROVED	18/07/2011
Mifepristone		for medical abortion in first trimester	APPROVED	28/07/2011
Mifepristone		for medical abortion in first trimester	APPROVED	28/07/2011
Mifepristone		for medical abortion in first trimester	APPROVED	28/07/2011
Mifepristone		for medical abortion in first trimester	APPROVED	28/07/2011
Mifepristone		for medical abortion in first trimester	APPROVED	28/07/2011
Mifepristone		for medical abortion in first trimester	APPROVED	28/07/2011
Mifepristone		for medical abortion in first trimester	APPROVED	28/07/2011
Mifepristone		for medical abortion in first trimester	APPROVED	28/07/2011
ALK-Abello Normal Saline with Phenol Diluent		for therapeutic and diagnostic use	APPROVED	8/07/2011
Allyostal skin prick testing reagents (Stallergenes)		Allergy Testing - skin prick test	APPROVED	19/07/2011
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	12/08/2011
cholecystekinin	Kinevac/ Sincalide	use in nuclear medicine biliary studies	APPROVED	15/08/2011
cholecystekinin	Kinevac/ Sincalide	for use in nuclear medicine biliary studies	APPROVED	25/08/2011
Indocyanine Green		ophthalmic angiography	APPROVED	15/08/2011
Indocyanine Green		during vitreo-retinal suegery and for intravenous injection to perform ICG angiography	APPROVED	15/08/2011
Multiple Allergens	ALK Abello USA Skin Testing Reagents	Skin prick testing for allergies	APPROVED	15/08/2011
Multiple Allergen Skin Test Reagents	Alyostal - Stallergenes	Skin prick testing for allergies	APPROVED	15/08/2011
Human Serum Albumin with Phenol diluent	ALK-Abello	for therapeutic and diagnostic management of allergic disease	APPROVED	15/08/2011
Normal Saline with Phenol diluent	ALK-Abello	for therapeutic and diagnostic management of allergic disease	APPROVED	15/08/2011
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	25/08/2011
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality	APPROVED	27/09/2011
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality	APPROVED	27/09/2011
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	pretern neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality	APPROVED	27/09/2011
OPAL A Filtrate and Cream		chronic venous and pressure ulcers	APPROVED	30/09/2011

Multiple Allergen Skin Prick Test Reagents	ALK-Abello	For skin prick testing for diagnostic allergy testing	APPROVED	23/09/2011
Multiple Allergen Skin Prick Test Reagents	Alyostal	For skin prick testing for diagnostic allergy testing	APPROVED	23/09/2011
DAP-kit [penicilloyl-poly-L (PPL) and minor determinant mixture (MDM)]		for penicillin allergy skin prick testing	APPROVED	23/09/2011
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK Abello Skin Prick Testing reagents	skin prick testing for allergies	APPROVED	27/07/2011
Human Serum Albumin with Phenol Diluent	Human Serum Albumin with Phenol	for therapeutic and diagnostic use	APPROVED	27/07/2011
Normal Saline with Phenol Diluent	ALK-Abello	for therapeutic and diagnostic use	APPROVED	27/07/2011
cholecystekinin	Kinevac/ Sincalide	use in nuclear medicine biliary studies	APPROVED	25/08/2011
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for diagnostic allergy testing.	APPROVED	25/08/2011
DAP-kit [penicilloyl-poly-L (PPL) and minor determinant mixture (MDM)]		to confirm or refute penicillin allergy in patients who require penicillin therapy	APPROVED	25/08/2011
Normal Saline with Phenol Diluent		For therapeutic and diagnostic management of allergic disease.	APPROVED	25/08/2011
Human Serum Albumin with Phenol Diluent	ALK-Abello	For therapeutic and diagnostic management of allergic disease.	APPROVED	25/08/2011
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	13/09/2011
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for diagnostic allergy testing	APPROVED	13/09/2011
DAP-kit [penicilloyl-poly-L (PPL) and minor determinant mixture (MDM)]		skin prick testing for diagnostic allergy testing	APPROVED	25/08/2011
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography.	APPROVED	22/11/2011
cholecystokinin	Sincalide, Kinevac	for imaging of the biliary tract	APPROVED	25/08/2011
cholecystekinin	Kinevac/ Sincalide	use in nuclear medicine biliary studies	APPROVED	25/08/2011
Cholecystokinin	Sincalide, Kinevac	for imaging of the biliary tract	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal D forte	for the treatment of moderate to severe vitamin D deficiency	APPROVED	12/09/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011

Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Mifepristone		Termination of pregnancy where medical abortion is assessed clinically as the most appropriate method for the woman, including when surgical abortion is not available.	APPROVED	26/08/2011
Corticotrophin Releasing Hormone (CRH)		diagnosis of Cushing's Syndrome	APPROVED	6/09/2011
cholecystekinin	Kinevac/ Sincalide	for use in nuclear medicine biliary studies	APPROVED	23/09/2011
Sodium Benzoate (intravenous injection 2 g/10 mL and oral tablets 500 mg)		for treatment of urea cycle disorders	APPROVED	6/09/2011
Sodium Benzoate (intravenous injection 2 g/10 mL and oral tablets 500 mg)		for treatment of urea cycle disorders	APPROVED	6/09/2011
Sodium Benzoate (intravenous injection 2 g/10 mL and oral tablets 500 mg)		for treatment of urea cycle disorders	APPROVED	6/09/2011
Sodium Benzoate (intravenous injection 2 g/10 mL and oral tablets 500 mg)		for treatment of urea cycle disorders	APPROVED	6/09/2011
Sodium Benzoate (intravenous injection 2 g/10 mL and oral tablets 500 mg)		for treatment of urea cycle disorders	APPROVED	6/09/2011
cholecystekinin		for nuclear medicine biliary studies	APPROVED	23/09/2011
Multiple Food Allergens	Alyostal	for diagnostic purposes in patients who require skin prick allergy tests	APPROVED	23/09/2011
Metolazone 5mg	Zaroxolyn/Diulo	the treatment of oedema or fluid retention unresponsive to other diuretics in patients with heart failure	APPROVED	6/09/2011
cholecalciferol 1.25mg	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	25/08/2011
DAP-Kit [penicilloyl-poly-l-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	23/09/2011
Cholecystokinin	Sincalide (Kinevac)	for assessment of gall bladder function in patients with suspected chronic acalculous cholecystitis	APPROVED	23/09/2011
Sodium Benzoate		in patients with: urea cycle disorders, nonketotic hyperglycinaemia and acute neonatal hyperammonaemia due to other metabolic disorders (including organic acidurias, methylmalonic acidaemia and propionic acidaemia)	APPROVED	6/09/2011

Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	21/09/2011
Human Serum Albumin with Phenol Diluent	ALK-Abello	for therapeutic and diagnostic management of allergic disease	APPROVED	21/09/2011
Normal Saline with Phenol Diluent	ALK-Abello	for therapeutic and diagnostic management of allergic disease	APPROVED	21/09/2011
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergies	APPROVED	21/09/2011
DAP-Kit [penicilloyl-poly-l-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	21/09/2011
Flammacerium	silversulfadiazine 10mg/g, 22mg/g cerium nitrate	for wound management of full thickness burns	APPROVED	23/09/2011
DAP-Kit [penicilloyl-poly-l-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	23/09/2011
Multiple Allergen Skin Test Reagents(Alyostal)		for skin prick testing for allergies	APPROVED	23/09/2011
Lutetium-177 Octreotate		for the treatment of metastatic neuroendocrine tumours	APPROVED	23/09/2011
Lutetium-177 Octreotate		for the treatment of metastatic neuroendocrine tumours	APPROVED	23/09/2011
Lutetium-177 Octreotate		for the treatment of metastatic neuroendocrine tumours	APPROVED	23/09/2011
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	13/09/2011
Triamcinolone Hexacetonide		for intra-articular injection in children with inflammatory arthritis	APPROVED	6/09/2011
Mifepristone		To improve the outcome of therapeutic termination of Pregnancy	APPROVED	17/02/2012
Mifepristone		To improve the outcome of therapeutic termination of Pregnancy	APPROVED	17/02/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	23/09/2011
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	23/09/2011
Human Serum Albumin with Phenol Diluent		for therapeutic and diagnostic management of allergic disease	APPROVED	23/09/2011
Normal Saline with Phenol Diluent		for therapeutic and diagnostic management of allergic disease	APPROVED	23/09/2011
DAP-Kit [penicilloyl-poly-l-lysine (PPL) and minor determinant mixture (MDM)]		for penicillin allergy testing	APPROVED	23/09/2011
Methacholine		to assess airway bronchial hyperresponsiveness	APPROVED	12/09/2011
Methacholine		to assess airway bronchial hyperresponsiveness	APPROVED	12/09/2011
cholecalciferol 1.25mg	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	6/09/2011
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergy testing.	APPROVED	23/09/2011

Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergy testing.	APPROVED	23/09/2011
Human Serum Albumin with Phenol Diluent	ALK-Abello	For therapeutic and diagnostic management of allergic disease.	APPROVED	9/11/2011
Normal Saline with Phenol Diluent	ALK-Abello	For therapeutic and diagnostic management of allergic disease.	APPROVED	9/11/2011
DAP-Kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	23/09/2011
Mifepristone		for medical termination of an intra-uterine pregnancy up to 63 days	APPROVED	10/01/2012
Mifepristone		for medical termination of an intra-uterine pregnancy up to 63 days	APPROVED	10/01/2012
Mifepristone		for medical termination of an intra-uterine pregnancy up to 63 days	APPROVED	10/01/2012
Mifepristone		for medical termination of an intra-uterine pregnancy up to 63 days	APPROVED	10/01/2012
cholecystokinin	sincalide	for imaging of the biliary tract	APPROVED	23/09/2011
cholecystokinin		for imaging of the biliary tract	APPROVED	23/09/2011
cholecalciferol		for moderate to severe Vitamin D deficiency	APPROVED	27/09/2011
Levomepromazine		for treatment of nausea and vomiting, delirium and terminal agitation in palliative care patients	APPROVED	22/09/2011
Levomepromazine		for treatment of nausea and vomiting, delirium and terminal agitation in palliative care patients	APPROVED	22/09/2011
Indocyanine Green		diagnosis of retinal pathologies	APPROVED	8/11/2011
cholecystekinin		to facilitate investigation of gall bladder function	APPROVED	14/11/2011
Human Serum Albumin with Phenol Diluent	ALK-Abello Human Serum Albumin with Phenol Diluent	for therapeutic and diagnostic use	APPROVED	9/11/2011
Normal Saline with Phenol Diluent	ALK-Abello Normal Saline with Phenol Diluent	for therapeutic and diagnostic use	APPROVED	9/11/2011
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	for skin prick allergy testing	APPROVED	9/11/2011
DAP-Kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	9/11/2011
Multiple Allergen Skin Test Reagents (ALK-Abello)	Alk-Abello	for skin prick testing for allergies	APPROVED	9/11/2011
Indocyanine Green		visualisation of blood vessels during neurosurgery	APPROVED	14/11/2011
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012
Indocyanine Green		visualisation of blood vessels during neurosurgery	APPROVED	14/11/2011
Indocyanine Green		visualisation of blood vessels during neurosurgery	APPROVED	14/11/2011
cholecalciferol		vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol		vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol		vitamin D deficiency	APPROVED	7/11/2011
cholecalciferol		vitamin D deficiency	APPROVED	15/11/2011

cholecalciferol 1.25mg		moderate to severe Vitamin D deficiency	APPROVED	15/11/2011
cholecalciferol 1.25mg		moderate to severe Vitamin D deficiency	APPROVED	7/11/2011
triamcinolone hexacetonide	Aristospan	Intra-articular injection for treatment purposes in patients with inflammatory arthritis in Juvenile Idiopathic Arthritis (JIA)	APPROVED	24/10/2011
ALK-Abello skin prick testing reagents for allergy testing		management of allergic disease	APPROVED	9/11/2011
Oestradiol Implant	Estrapel Implant 50mg	Management of oestrogen deficiency symptoms due to natural or surgical menopause	APPROVED	14/10/2011
cholecalciferol 50,000 iu	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	7/11/2011
Mifepristone		Severe maternal medical disease contraindicating the continuation of pregnancy in 1st & 2nd trimester of pregnancy. Foetal abnormality in 1st & 2nd trimester. intrauterine fetal demise in 1st & 2nd trimester	APPROVED	9/11/2011
DAP-kit [penicilloyl-poly-L (PPL) and minor determinant mixture (MDM)]		for skin prick testing for diagnosis of penicillin allergy	APPROVED	14/11/2011
Indocyanine green		for intravenous injection to perform ICG angiography	APPROVED	14/11/2011
Diater DAP-kit (penicilloyl-poly-L (PPL) and minor determinant mixture (MDM))		intradermal skin prick and desensitization procedures	APPROVED	14/11/2011
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	2/12/2011
Multiple Allergen Skin Test Reagents	ALK-Abello	to diagnose allergic triggers in patients	APPROVED	14/11/2011
Multiple Allergen Skin Test Reagents	Alyostal	for skin testing allergic diseases	APPROVED	14/11/2011
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	17/11/2011
Mifepristone		for medical termination of an intra-uterine pregnancy up to 63 days	APPROVED	16/01/2012
pyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
pyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
pyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
pyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
pyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
pyrazinamide		for the treatment of tuberculosis	APPROVED	22/11/2011
Mifepristone		Medical abortion to 63 days gestation. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	16/01/2012
triamcinolone hexacetonide		Intra-articular injection for treatment purposes in patients with inflammatory arthritis in Juvenile Idiopathic Arthritis (JIA)	APPROVED	22/11/2011
Cholecalciferol 1.25mg (50,000iu)	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
Indocyanine Green		evaluation of liver function	APPROVED	6/12/2011
Cholecystokinin	sincalide	for imaging of the biliary tract.	APPROVED	6/12/2011
DAP-Kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	15/12/2011

Diater DAP skin prick testing reagents		Penicillian allergy testing	APPROVED	15/12/2011
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	14/12/2011
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	10/01/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	10/01/2012
Mifepristone		termination of pregnancy up to 49 days gestation	APPROVED	28/02/2012
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria	APPROVED	15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria	APPROVED	15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria	APPROVED	15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria	APPROVED	15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria	APPROVED	15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria	APPROVED	15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria	APPROVED	15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria	APPROVED	15/12/2011
Primacin Tablets 7.5mg (primaquine base)		prevention of relapses (radical cure) of malaria caused by P. Vivax and P. Ovale.; - adjunctive therapy in the treatment of gametocytemia due to P. Falciparum in patients resident in areas receptive to malaria	APPROVED	15/12/2011
Estrapel Oestradiol Implants		management of oestrogen deficiency symptoms due to natural or surgical menopause	APPROVED	2/03/2012
Cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergic disease	APPROVED	24/01/2012
Pirfenidone		Idiopathic Pulmonary Fibrosis	APPROVED	26/03/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	13/01/2012
DAP-Kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	Diater DAP-Kit	for penicillin allergy testing	APPROVED	6/02/2012
Triamcinolone Acetonide		Macular Oedema	APPROVED	16/01/2012

[illegible]

Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	27/02/2012
Cholecalciferol 1.25mg (50,000iu)	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
Cholecalciferol 1.25mg (50,000iu)	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
Cholecalciferol 1.25mg (50,000iu)	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
Indocyanine Green		for intravenous injection to perform retinal angiography	APPROVED	17/08/2012
Cholecalciferol 1.25mg (50,000iu)	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	27/01/2012
Indocyanine Green		Vitreo-retinal surgery & intravenous injection to perform ICG angiography	APPROVED	6/02/2012
Indocyanine Green		Vitreo-retinal surgery & intravenous injection to perform ICG angiography	APPROVED	6/02/2012
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	6/02/2012
Diater DAP Skin Prick Testing Reagents		Penicillin and Amoxycillin allergy testing	APPROVED	13/02/2012
Alyostal Skin Prick Testing Reagents (Stallergenes)		allergy testing	APPROVED	6/02/2012
ALK-Abello Skin Prick Testing Reagents (Stallergenes)		allergy testing	APPROVED	6/02/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	3/02/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	3/02/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	3/02/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	3/02/2012
Indocyanine Green		vitreo-retinal surgery and intravenous injection to perform ICG angiography	APPROVED	13/02/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	13/02/2012
Mifepristone		for medical abortion in first trimester	APPROVED	3/02/2012

Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	3/02/2012
Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hvdrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	3/02/2012
Cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	20/03/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	19/10/2012
cholecalciferol 1.25mg	Cal D Forte	moderate to severe Vitamin D deficiency	APPROVED	31/07/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	28/02/2012
methacholine		for bronchial provocation testing	APPROVED	16/02/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	28/02/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergies	APPROVED	28/02/2012
Patanase Nasal Spray (600ug olopatadine hydrochloride)		Allergic rhinitis/patients who have failed currently available therapies	APPROVED	29/06/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	23/02/2012
Multiple Allergen Skin Test Reagents(ALK-Abello)	ALK Abello	for skin prick testing for allergies	APPROVED	27/02/2012
Normal Saline with Phenol (ALK-Abello)		for skin prick testing for allergies	APPROVED	27/02/2012
ALK-Abello Normal Saline with Phenol (NSA) diluent		for skin prick testing for allergy testing.	APPROVED	20/03/2012
ALK-Abello Human Serum Albumin (HSA) diluent		for skin prick testing for allergy testing.	APPROVED	20/03/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	7/03/2012
cholecalciferol 50,000 iu		treatment of Vitamin D deficiency in patients with levels < 50mmol/L	APPROVED	13/09/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	9/03/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	16/03/2012
cholecalciferol 1.25mg	Cal. D. Forte	for treatment of moderate to severe Vitamin D deficiency	APPROVED	13/03/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	20/03/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	20/03/2012
Mifepristone		Termination of pregnancies in mid-trimester pregnancies	APPROVED	17/02/2012
Estrapel Oestradiol Implants		management of oestrogen deficiency symptoms due to natural or surgical menopause	APPROVED	9/03/2012
Histamine Dichloride (1% in 3mL)		positvie control for skin prick testing for allergies	APPROVED	28/02/2012

Fosfomycin tromethamine		for treatment of lower urinary tract infections caused by multi-drug resistant gram negative organisms (ESBL)	APPROVED	2/07/2012
Cholecystokinin	Kinevac/ Sincalide	for imaging of the biliary tract.	APPROVED	29/03/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus)	APPROVED	29/08/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus)	APPROVED	29/08/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Mifepristone		Medical abortion in 1st trimester up to 63 days. Medical abortion in 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Mifepristone		Medical abortion up to 63 days of preg in women suffering from life-threatening or otherwise serious illnesses or conditions where continuing the pregnancy poses greater risks to the woman's life or health than does induced abortion. *See approval letter*	APPROVED	11/05/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	30/03/2012
Multiple Allergen Skin Test Reagents(ALK-Abello)		skin prick testing for diagnostic allergy testing	APPROVED	20/04/2012
Diater DAP-kit [penicilloyl-poly-L (PPL) and minor determinant mixture (MDM)]	benzylpenicilloyl-polylysine (stallergenes Allergopen), sodium	for penicillin allergy skin prick testing	APPROVED	20/04/2012
Alyostal Multiple Allergens	Alyostal Skin Testing Reagents	Skin prick testing for allergies	APPROVED	20/04/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	preterm neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality	APPROVED	21/03/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	preterm neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality	APPROVED	21/03/2012
Mannitol	Bronchitol	treatment of bronchiectasis	APPROVED	10/04/2012
Levomopromazine		to treat nausea, vomiting, delirium agitation in palliative care terminal patients	APPROVED	27/03/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	28/03/2012
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	29/03/2012
Multiple Allergen Skin Test Reagents		skin prick testing for allergies	APPROVED	29/03/2012
Edrophonium Chloride		Myasthenia Gravis	APPROVED	5/04/2012

[illegible]

Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone 200mg		Midtrimester termination of pregnancy	APPROVED	31/05/2012
Mifepristone		for medical abortion in first trimester	APPROVED	14/06/2012
Mifepristone		for medical abortion in first trimester	APPROVED	14/06/2012
Multiple Allergen Skin Test Reagents(ALK-Abello)	ALK Abello	for skin prick testing for diagnostic allergy testing	APPROVED	1/06/2012
Diater DAP skin prick testing reagents		Penicillian AND Amoxycillin allergy testing	APPROVED	1/06/2012
Multiple Allergen Skin Test Reagents (Alyostal)		allergy testing	APPROVED	1/06/2012
Cholecalciferol 1.25mg		Moderate to severe Vitamin D deficiency	APPROVED	6/06/2012
Cholecalciferol 1.25mg		Moderate to severe Vitamin D deficiency	APPROVED	6/06/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	4/06/2012
Progesterone (Utrogestan) 100mg and 200mg		management of menopausal symptoms	APPROVED	4/06/2012
Dydrogesterone (Duphaston) 5-10mg tablets		management of oestrogen deficiency symptoms due to natural or surgical menopause	APPROVED	4/06/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	4/06/2012
Triamcinolone Acetonide		posterior segment uveitis and intraoperative identification of vitreous	APPROVED	25/09/2012
Triamcinolone Acetonide		posterior segment uveitis and intraoperative identification of vitreous	APPROVED	25/09/2012
Triamcinolone Acetonide		posterior segment uveitis and intraoperative identification of vitreous	APPROVED	25/09/2012
Triamcinolone Acetonide		posterior segment uveitis and intraoperative identification of vitreous	APPROVED	25/09/2012
5 Methoxypsoralen	Pentaderm	requiring treatment for psoriasis and vitiligo	APPROVED	5/06/2012
Multiple Allergen Test Reagents		for skin prick testing for allergy testing	APPROVED	12/06/2012
Fosfomycin		for treatment of lower urinary tract infections caused by multi-drug resistant gram negative organisms (ESBL)	APPROVED	6/06/2012
DAP-kit [penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)]	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for skin prick and intradermal allergy testing for investigation of beta-lactam/penicillin	APPROVED	6/06/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus) conditions	APPROVED	29/08/2012
cholecalciferol 1ml injection	D3- Forte	Vitamin D deficiency and malabsorption	APPROVED	29/06/2012
Cyclizine		nausea and vomiting	APPROVED	29/06/2012
Levomepromazine		nausea and vomiting	APPROVED	29/06/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus) conditions	APPROVED	29/08/2012
pyrazinamide		treatment of Tuberculosis	APPROVED	2/07/2012

pyrazinamide		treatment of Tuberculosis	APPROVED	2/07/2012
pyrazinamide		treatment of Tuberculosis	APPROVED	2/07/2012
Progesterone (Utrogestan) 100mg and 200mg		uterine protection while on Oestrogen	APPROVED	17/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012

Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012

Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012

Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012

Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012

Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012

Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	2/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Pollypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Pollypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012

Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Mifepristone		for medical abortion in first trimester (up to 63 days), medical abortion in 2nd trimester (up to 17 weeks), cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	19/06/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Bifidobacterium Bifidum & Lactobacillus Acidophilus	Infloran	for treatment of preterm who have a gestational age at birth of less than 32 weeks or birth weight less than 1500 grams and on enteral feed for at least 48 hours for prevention of necrotising enterocolitis (NEC)	APPROVED	24/07/2012
Mifepristone		for medical abortion in first trimester	APPROVED	17/07/2012

clobetasol		to treat dermatoses that are non-responsive to weaker topical steroids eg psoriasis, eczema, cutaneous lupus, lichen planus, pyoderma gangrenosum and other potentially resistant less common dermatoses	APPROVED	29/08/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012

Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012

Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	13/09/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012

Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	24/07/2012
Progesterone (Utrogestan) 100mg & 200mg capsules	Utrogestan	for short term treatment of oestrogen deficiency symptoms in women with an intact uterus	APPROVED	6/08/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus) conditions	APPROVED	29/08/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus) conditions	APPROVED	29/08/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus) conditions	APPROVED	29/08/2012
Multiple Allergens - Alyostal		Skin prick testing for diagnostic allergy testing	APPROVED	10/08/2012
Multiple Allergens - Alyostal		Skin prick testing for diagnostic allergy testing	APPROVED	10/08/2012
Multiple Allergen SkinTest Reagents - ALK Abello		Skin prick testing for diagnostic allergy testing	APPROVED	31/07/2012
Diater DAP Penicillin and Amoxycillin SkinTest Reagents		for skin testing to investigate allergy to beta-lactam antibiotics	APPROVED	10/08/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	31/07/2012
Indocyanine Green		Suspected polypoidal choroidal vasculopathy	APPROVED	31/07/2012
cholecalciferol		moderate to severe Vitamin D deficiency	APPROVED	23/08/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	10/08/2012

[illegible]

[illegible]

Multiple Allergen Skin Test Reagents		skin prick testing for allergies	APPROVED	22/08/2012
Mifepristone		Medical abortion when this is assessed as the best clinical option for the individual woman	APPROVED	3/09/2012
Mifepristone		Medical abortion when this is assessed as the best clinical option for the individual woman	APPROVED	3/09/2012
Mifepristone		Medical abortion when this is assessed as the best clinical option for the individual woman	APPROVED	3/09/2012
Mifepristone		Termination of pregnancy where medical abortion is assessed as the best clinical option for the individual woman.	APPROVED	3/09/2012
Mifepristone		Termination of pregnancy where medical abortion is assessed as the best clinical option for the individual woman.	APPROVED	3/09/2012
Diater DAP-kit [penicilloyl-poly-L (PPL) and minor determinant mixture (MDM)]		for penicillin allergy skin prick testing	APPROVED	23/08/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	7/09/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for allergies	APPROVED	7/09/2012
ALK-Abello Human Serum Albumin with Phenol (HSA) diluent		skin prick testing for allergies	APPROVED	7/09/2012
ALK-Abello Normal Saline with Phenol (NSP) diluent		skin prick testing for allergies	APPROVED	7/09/2012
Cholecystokinin		nuclear medicine imaging for patients with gall bladder disease	APPROVED	23/08/2012
melatonin 5mg immediate release tablets		conditions where sleep patterns are disrupted, including those secondary to intellectual impairment, developmental delay or autism that are non responsive to hypnotics or sedatives	APPROVED	7/09/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	23/08/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	23/08/2012
Ethinylloestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Dydrogesterone (Duphaston) 10mg		uterine protection while on Oestrogen	APPROVED	28/08/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	29/08/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	7/09/2012

Testosterone Implant 75mg	Testopel Implant 75mg	management of hypoactive sexual desire disorder in postmenopausal women and women in their late reproductive years	APPROVED	7/09/2012
Indocyanine Green		investigation of retinal disease and tissue stain during vitrectomy	APPROVED	29/08/2012
Cyclizine 50mg tablets		nausea and vomiting in Palliative Care patients	APPROVED	3/09/2012
Levomepromazine tablets and ampoules		nausea and vomiting in Palliative Care patients	APPROVED	3/09/2012
Indocyanine Green		during retinal/choroidal angiography	APPROVED	29/08/2012
Indocyanine Green		during retinal/choroidal angiography	APPROVED	29/08/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	29/08/2012
L-Carnitine (intravenous)		inborn errors of metabolism, fatty acid oxidation and organic acidaemias	APPROVED	18/12/2012
Arginine (intravenous)		hyperammonaemia and urea cycle disorders	APPROVED	18/12/2012
L-Carnitine (intravenous)		inborn errors of metabolism, fatty acid oxidation and organic acidaemias	APPROVED	18/12/2012
Arginine (intravenous)		hyperammonaemia and urea cycle disorders	APPROVED	18/12/2012
Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	7/09/2012
enalaprilat		for use in renal venous renin ratio testing for patients undergoing renal venous ratio studies	APPROVED	7/09/2012
clobetasol		Dermatoses that are non-responsive to weaker topical steroids (e.g. Eczema, psoriasis, lichen planus, cutaneous lupus)	APPROVED	29/08/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnostic allergy testing	APPROVED	16/05/2013
Ethinylestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinylestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Ethinylestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	6/09/2012
mannitol	Bronchitol	bronchiectasis	APPROVED	6/09/2012
cholecystekinin		as a diagnostic test agent for investigation of biliary disorders	APPROVED	6/09/2012
cholecystekinin		as a diagnostic test agent for investigation of biliary disorders	APPROVED	6/09/2012
cholecystekinin		as a diagnostic test agent for investigation of biliary disorders	APPROVED	6/09/2012
cholecystekinin		as a diagnostic test agent for investigation of biliary disorders	APPROVED	6/09/2012
cholecystekinin		as a diagnostic test agent for investigation of biliary disorders	APPROVED	6/09/2012
Ethinylestradiol		to prepare the endometrium prior to transfer of frozen embryo	APPROVED	3/09/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012

Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	10/09/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	14/09/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	13/09/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	13/09/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	25/09/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	25/09/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	25/09/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	25/09/2012
cholecalciferol		moderate to severe vitamin D deficiency	APPROVED	25/09/2012
Perflutren Protein-Type A Microspheres Injectable Suspension	Optison	contrast agent for non-diagnostic echocardiogram	APPROVED	2/10/2012
Perflutren Protein-Type A Microspheres Injectable Suspension	Optison	contrast agent for non-diagnostic echocardiogram	APPROVED	2/10/2012
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	25/09/2012

Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	25/09/2012
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	25/09/2012
melatonin 3mg controlled release capsules		patients in whom the registered product is unsuitable with conditions where sleep patterns are disrupted, including those secondary to intellectual impairment, developmental delay or autism that are non responsive to hypnotics or sedatives	APPROVED	11/10/2012
Indocyanine Green		for use during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	10/10/2012
Gonadorelin (100 mcg injection)		to assess the pituitary gonadotropin response in disorders of puberty or gonadal function	APPROVED	16/10/2012
Gonadorelin (100 mcg injection)		to assess the pituitary gonadotropin response in disorders of puberty or gonadal function	APPROVED	16/10/2012
Gonadorelin (100 mcg injection)		to assess the pituitary gonadotropin response in disorders of puberty or gonadal function	APPROVED	16/10/2012
Gonadorelin (100 mcg injection)		to assess the pituitary gonadotropin response in disorders of puberty or gonadal function	APPROVED	16/10/2012
Gonadorelin (100 mcg injection)		to assess the pituitary gonadotropin response in disorders of puberty or gonadal function	APPROVED	16/10/2012
Gonadorelin (100 mcg injection)		to assess the pituitary gonadotropin response in disorders of puberty or gonadal function	APPROVED	16/10/2012
Gonadorelin (100 mcg injection)		to assess the pituitary gonadotropin response in disorders of puberty or gonadal function	APPROVED	16/10/2012
Gonadorelin (100 mcg injection)		to assess the pituitary gonadotropin response in disorders of puberty or gonadal function	APPROVED	16/10/2012
triamcinolone hexacetonide		juvenile idiopathic arthritis	APPROVED	11/10/2012
triamcinolone hexacetonide		juvenile idiopathic arthritis	APPROVED	11/10/2012
triamcinolone hexacetonide		juvenile idiopathic arthritis	APPROVED	11/10/2012
triamcinolone hexacetonide		juvenile idiopathic arthritis	APPROVED	11/10/2012
triamcinolone hexacetonide		juvenile idiopathic arthritis	APPROVED	11/10/2012
Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	11/10/2012

Polypill Version 1 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg) and Polypill Version 2 (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg)		for continuation of treatment of participants in Kanyini GAP Study (Protocol X08-0076) in accordance with study's approved inclusion and exclusion criteria	APPROVED	11/10/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	10/10/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	10/10/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	11/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	15/10/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	11/10/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	10/10/2012
cholecalciferol 1.25mg	Cal D forte, D-3-50	for the treatment of moderate to severe vitamin D deficiency	APPROVED	10/10/2012

Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnosis of allergies	APPROVED	17/01/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergy testing	APPROVED	12/02/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	for skin prick testing for allergy testing	APPROVED	12/02/2013
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	27/11/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	19/10/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	19/10/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	19/10/2012
pyrazinamide		for treatment of tuberculosis and multi-drug resistant tuberculosis	APPROVED	22/10/2012
flunarizine		Neurological Conditions such as migrane, hemiplegia, cerebral vasculopathy and Moya Moya Syndrome	APPROVED	19/10/2012
flunarizine		Neurological Conditions such as migrane, hemiplegia, cerebral vasculopathy and Moya Moya Syndrome	APPROVED	19/10/2012
flunarizine		Neurological Conditions such as migrane, hemiplegia, cerebral vasculopathy and Moya Moya Syndrome	APPROVED	19/10/2012
Stiripentol	stiripentol	severe myoclonic epilepsy in infancy (Dravet syndrome)	APPROVED	31/10/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)	Multiple allergen extracts	Skin prick testing for diagnostic allergy testing	APPROVED	19/10/2012
Multiple Allergen Skin Test Reagents (Alyostal)	Multiple allergen extracts	Skin prick testing for diagnostic allergy testing	APPROVED	19/10/2012
Oestradiol (Estrapel) sub cutaneous pellets 25mg & 50mg		releif of vasomotor and other symptoms of oestrogen deficiency in menopausal and perimenopausal women	APPROVED	10/01/2013
Oestradiol (Estrapel) sub cutaneous pellets 25mg & 50mg		releif of vasomotor and other symptoms of oestrogen deficiency in menopausal and perimenopausal women	APPROVED	4/04/2013
Progesterone (Utrogestan) 100mg & 200mg		endometrial protection in post menopausal women on systemic oestrogen therapy	APPROVED	19/10/2012
Dydrogesterone (Duphaston) 10mg		endometrial protection in post menopausal women on systemic oestrogen therapy	APPROVED	19/10/2012
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013

mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
mifepristone	Mifegyne	first trimester miscarriage, fetal abnormality, fetal death in utero, maternal illness, extreme premature prelabour rupture of membranes	APPROVED	15/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)		allergy skin prick testing	APPROVED	13/12/2012
Multiple Allergen Skin Prick Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	19/10/2012
Multiple Allergen Skin Prick Test Reagents (ALK-Abellol)		for skin prick testing for allergies	APPROVED	19/10/2012
Diater DAP Amoxycillin and Penicillin Skin Prick Test Reagents		for skin prick testing for allergies	APPROVED	29/10/2012
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	27/11/2012
Progesterone (Utrogestan) 100mg & 200mg		endometrial protection in post menopausal women on systemic oestrogen therapy	APPROVED	28/11/2012
Dydrogesterone (Duphaston) 10mg		endometrial protection in post menopausal women on systemic oestrogen therapy	APPROVED	27/11/2012
flunarizine		neurological conditions such as migrane, hemiplegia, cerebral vasculopathy, Moya Moya Syndrome	APPROVED	31/10/2012
Indocyanine Green		for intravenous injection to perform ICG angiography	APPROVED	25/10/2012
Indocyanine Green		for intravenous injection to perform ICG angiography	APPROVED	25/10/2012
Indocyanine Green		for intravenous injection to perform ICG angiography	APPROVED	25/10/2012
triamcinolone hexacetonide		for intra-articular therapy in juvenile idiopathic arthritis	APPROVED	27/11/2012
triamcinolone hexacetonide		for intra-articular therapy in juvenile idiopathic arthritis	APPROVED	27/11/2012
triamcinolone hexacetonide		for intra-articular therapy in juvenile idiopathic arthritis	APPROVED	27/11/2012
glycopyrronium bromide 0.05%	glycopyrronium bromide	for the treatment of palmo and plantar hyperhidrosis	APPROVED	27/11/2012
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	27/11/2012
Diater (DAP) Determinants Allergy Penicillin	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	skin testing for penicillin allergy	APPROVED	31/10/2012

[illegible]

cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Steuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Steuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Steuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Steuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Steuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Steuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Steuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Steuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	31/10/2012
cholecalciferol (Cal D Forte) 1.25mg or 50,000 IU		moderate to severe Vitamin D deficiency	APPROVED	27/11/2012
cholecalciferol 1.25mg (50,000 iu)		for the treatment of moderate to severe Vitamin D deficiency	APPROVED	14/11/2012

Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	15/11/2012
Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Bifidobacterium infantis & Lactobacillus acidophilus(Infloran)	Infloran	for treatment of preterm neonates who have a gestational age at birth of less than 32 weeks for prevention of necrotising enterocolitis (NEC)	APPROVED	14/11/2012
Penicillin Allergy Determinants (DAP) - Diater	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for testing and identification of drug allergy to beta lactam antibiotics	APPROVED	27/11/2012
Penicillin Allergy Determinants (DAP) - Diater	penicilloyl-poly-L-lysine (PPL) and minor determinant mixture (MDM)	for testing and identification of drug allergy to beta lactam antibiotics	APPROVED	27/11/2012
Multiple Allergen skin Test Reagents (Alyostal)	Alyostal Skin testing reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	skin prick testing for diagnosis of allergies	APPROVED	27/11/2012
Diater DAP Penicillin and Amoxycillin Skin Prick Test Reagents		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	27/11/2012
Diater DAP Penicillin and Amoxycillin Skin Prick Test Reagents		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	27/11/2012

Diater DAP Penicillin and Amoxycillin Skin Prick Test Reagents		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	27/11/2012
Diater DAP Penicillin and Amoxycillin Skin Prick Test Reagents		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	27/11/2012
Diater DAP Penicillin and Amoxycillin Skin Prick Test Reagents		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	14/12/2012
Diater DAP Penicillin and Amoxycillin Skin Prick Test Reagents		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	27/11/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	skin prick testing for diagnosis of allergies	APPROVED	27/11/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	skin prick testing for diagnosis of allergies	APPROVED	27/11/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	skin prick testing for diagnosis of allergies	APPROVED	27/11/2012
Multiple Allergen skin Test Reagents (Alyostal)	Alyostal Skin testing reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/2012
Multiple Allergen skin Test Reagents (Alyostal)	Alyostal Skin testing reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/2012
Multiple Allergen skin Test Reagents (Alyostal)	Alyostal Skin testing reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/2012
Multiple Allergen skin Test Reagents (Alyostal)	Alyostal Skin testing reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/2012
Multiple Allergen skin Test Reagents (Alyostal)	Alyostal Skin testing reagents	skin prick testing for diagnosis of allergies allergies	APPROVED	28/11/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	21/12/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	21/12/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	21/12/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	21/12/2012
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	21/12/2012
corticotrophin releasing hormone	Corticotropin (CRH)	as a diagnostic agent during Inferior Petrosal Sinus sampling for confirmation that a patient's excess ACTH production is from the pituitary gland	APPROVED	15/03/2013
gonadorelin	LHRH (gonadotrophin releasing hormones)	evaluation of functional capacity and response of gonadotrophic hormones (LH and FSH) in adults suspected of pituitary failure or evaluation of delayed puberty	APPROVED	15/03/2013

thyrotropin releasing hormone	Protirelin (TRH)	as an adjunct to other diagnostic procedures in patients with pituitary or hypothalamic dysfunction	APPROVED	14/03/2013
Sodium Benzoate		in patients with: urea cycle disorders, nonketotic hyperglycinaemia and acute neonatal hyperammonaemia due to other metabolic disorders (including organic acidurias, methylmalonic acidemia and propionic acidemia)	APPROVED	18/12/2012
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
Mifepristone		Medical abortion in 1st and 2nd trimester (foetal abnormalities, serious/life threatening condition)..Cervical Priming prior to surgical abortion in the 1st and 2nd trimesters	APPROVED	21/12/2012
Mifepristone		Medical abortion in 1st and 2nd trimester (foetal abnormalities, serious/life threatening condition)..Cervical Priming prior to surgical abortion in the 1st and 2nd trimesters	APPROVED	21/12/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	17/12/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	17/12/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	18/12/2012
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	18/12/2012
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	18/12/2012
Melatonin 3mg capsule		patients with a sleep/ wake cycle disturbance	APPROVED	19/12/2012
Mifepristone		for medical abortion in the first trimester	APPROVED	9/01/2013
Mifepristone		for medical abortion in the first trimester	APPROVED	9/01/2013
Mifepristone		for medical abortion in the first trimester	APPROVED	9/01/2013
Perflutren Protein-Type A Microspheres Injectable Suspension	Optison	for use in patients with suboptimal echocardiogram	APPROVED	18/12/2012
Stabilised Ceretec (technetium 99mTc exametazine injection)		for cerebral perfusion imaging, ictal studies and epilepsy	APPROVED	19/12/2012
Stabilised Ceretec (technetium 99mTc exametazine injection)		for cerebral perfusion imaging, ictal studies and epilepsy	APPROVED	19/12/2012
Stabilised Ceretec (technetium 99mTc exametazine injection)		for cerebral perfusion imaging, ictal studies and epilepsy	APPROVED	19/12/2012
Stabilised Ceretec (technetium 99mTc exametazine injection)		for cerebral perfusion imaging, ictal studies and epilepsy	APPROVED	18/12/2012

[illegible]

Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in the Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
Lorazepam Injection, USP		for Sedation/Tranquilisation as indicated in Justice Health Psychotropic Medications Guidelines Chapter Three - Rapid Tranquilisation	APPROVED	20/05/2013
cholecalciferol 1.25mg (50,000IU) capsule D3-50	D3-50	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
cholecalciferol 1.25mg (50,000IU) capsule D3-50	D3-50	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
cholecalciferol 1.25mg (50,000IU) capsule D3-50	D3-50	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
cholecalciferol 1.25mg (50,000IU) capsule D3-50	D3-50	moderate to severe Vitamin D deficiency	APPROVED	15/01/2013
Mifepristone		Medical abortion in 1st and 2nd trimester. Cervical priming prior to surgical abortion in 1st and 2nd trimesters	APPROVED	25/01/2013
Mifepristone		medical abortion in the first trimester	APPROVED	25/01/2013
Mifepristone		medical abortion in the first trimester	APPROVED	25/01/2013
Mifepristone		medical abortion in the first trimester	APPROVED	25/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing in allergy testing	APPROVED	30/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing in allergy testing	APPROVED	30/01/2013
Multiple Allergens - Alyostal	Alyostal/Stallergenes	for testing of allergies in the management of allergic disease	APPROVED	30/01/2013
Multiple Allergens - Alyostal	Alyostal/Stallergenes	for testing of allergies in the management of allergic disease	APPROVED	30/01/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	for therapeutic and diagnostic use.	APPROVED	12/02/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for allergies	APPROVED	12/02/2013
Normal Saline with Phenol Diluents (ALK-Abello NSP)		skin prick testing for allergies	APPROVED	12/02/2013
Diater DAP Penicillin and Amoxycillin Skin Test Reagents	ALK-Abello	for skin prick testing for allergy testing	APPROVED	12/02/2013

Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergy testing	APPROVED	12/02/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	for skin prick testing for allergy testing	APPROVED	12/02/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergy testing	APPROVED	12/02/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	for skin prick testing for allergy testing	APPROVED	12/02/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for allergies	APPROVED	12/02/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	12/02/2013
Gallium-68 labelled octreotide analogues (68Ga-DOTATATE, 68Ga-DOTANOC, 68Ga-DOTATOC)		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2. Exclusion of additional disease sites; 3. Diagnostic localisation of phaeochromocytomas, paragangliomas, ganglioneuroblastomas and ganglioneuromas; 4. Assessment of tumour burden.	APPROVED	22/02/2013
Gallium-68 labelled octreotide analogues (68Ga-DOTATATE, 68Ga-DOTANOC, 68Ga-DOTATOC)		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2. Exclusion of additional disease sites; 3. Diagnostic localisation of phaeochromocytomas, paragangliomas, ganglioneuroblastomas and ganglioneuromas; 4. Assessment of tumour burden.	APPROVED	22/02/2013
Gallium-68 labelled octreotide analogues (68Ga-DOTATATE, 68Ga-DOTANOC, 68Ga-DOTATOC)		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2. Exclusion of additional disease sites; 3. Diagnostic localisation of phaeochromocytomas, paragangliomas, ganglioneuroblastomas and ganglioneuromas; 4. Assessment of tumour burden.	APPROVED	22/02/2013
Gallium-68 labelled octreotide analogues (68Ga-DOTATATE, 68Ga-DOTANOC, 68Ga-DOTATOC)		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2. Exclusion of additional disease sites; 3. Diagnostic localisation of phaeochromocytomas, paragangliomas, ganglioneuroblastomas and ganglioneuromas; 4. Assessment of tumour burden.	APPROVED	22/02/2013
Gallium-68 labelled octreotide analogues (68Ga-DOTATATE, 68Ga-DOTANOC, 68Ga-DOTATOC)		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2. Exclusion of additional disease sites; 3. Diagnostic localisation of phaeochromocytomas, paragangliomas, ganglioneuroblastomas and ganglioneuromas; 4. Assessment of tumour burden.	APPROVED	22/02/2013
Gallium-68 labelled octreotide analogues (68Ga-DOTATATE, 68Ga-DOTANOC, 68Ga-DOTATOC)		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2. Exclusion of additional disease sites; 3. Diagnostic localisation of phaeochromocytomas, paragangliomas, ganglioneuroblastomas and ganglioneuromas; 4. Assessment of tumour burden.	APPROVED	22/02/2013
Gallium-68 labelled octreotide analogues (68Ga-DOTATATE, 68Ga-DOTANOC, 68Ga-DOTATOC)		1. Detection of suspected gastroenteropancreatic endocrine tumour; 2. Exclusion of additional disease sites; 3. Diagnostic localisation of phaeochromocytomas, paragangliomas, ganglioneuroblastomas and ganglioneuromas; 4. Assessment of tumour burden.	APPROVED	22/02/2013
Indocyanine Green		retinal angiography in ophthalmic practice	APPROVED	11/04/2013
Indocyanine Green		for use in retinal angiography	APPROVED	22/02/2013
Indocyanine Green		for use in retinal angiography	APPROVED	22/02/2013
Indocyanine Green		for use in retinal angiography	APPROVED	22/02/2013
Melatonin capsules		sleep disturbance in children with developmental disabilities	APPROVED	22/02/2013
L-Carnitine (oral and intravenous forms)		inborn errors of protein metabolism (organic acidaemias), fatty acid oxidation defects, primary carnitine deficiency, chronic depletion, nutritional deficiency and cardiomyopathy	APPROVED	22/02/2013

L-Carnitine (oral and intravenous forms)		inborn errors of protein metabolism (organic acidaemias), fatty acid oxidation defects, primary carnitine deficiency, chronic depletion, nutritional deficiency and cardiomyopathy	APPROVED	22/02/2013
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	1/03/2013
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Steuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	4/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Multiple allergen extracts	skin prick testing for allergic diseases	APPROVED	8/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	1/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	1/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	1/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	21/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	1/03/2013
cholecalciferol 1.25mg (50,000IU)	Cal D Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	24/04/2013
PEG-asparaginase		for treatment of children with acute lymphoblastic leukaemia	APPROVED	5/03/2013
Indocyanine Green		for retinal angiography	APPROVED	8/03/2013
Moorfields phenylephrine 0.6% intracameral syringe		for floppy iris syndrome in patients undergoing cataract surgery	APPROVED	8/03/2013
Moorfields phenylephrine 0.6% intracameral syringe		for floppy iris syndrome in patients undergoing cataract surgery	APPROVED	8/03/2013
Moorfields phenylephrine 0.6% intracameral syringe		for floppy iris syndrome in patients undergoing cataract surgery	APPROVED	8/03/2013
Indocyanine Green		for retinal angiography	APPROVED	8/03/2013
Indocyanine Green		for retinal angiography	APPROVED	8/03/2013
Glycopyrrolate 1mg tablets		treatment of excessive salivation and drooling (sialorrhoea) in patients with advanced neuromuscular disease	APPROVED	5/03/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for allergies	APPROVED	8/03/2013
Glycopyrrolate 1mg tablets		for control of excessive salivary secretions in children with developmental disabilities	APPROVED	5/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	8/03/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for allergy testing	APPROVED	16/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergy testing	APPROVED	16/05/2013

Diater DAP Penicillin and Amoxycillin Skin Test Reagents		for skin prick testing for allergy testing	APPROVED	16/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	15/03/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		for skin prick testing for allergies	APPROVED	15/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		for skin prick testing for allergies	APPROVED	15/03/2013
cholecalciferol 1.25mg (50,000 IU)	D-3-50, Cal-D-Forte	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D-3-50, Cal-D-Forte	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D-3-50, Cal-D-Forte	moderate to severe vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D-3-50, Cal-D-Forte	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
cholecalciferol 1.25mg (50,000 IU)	D 3-50	moderate to severe Vitamin D deficiency	APPROVED	5/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	21/03/2013
Diater DAP Penicillin and Amoxycillin Skin Test Reagents		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Indocyanine Green		measurement of ICG retention (liver function) using Pulsion Limon Monitor	APPROVED	21/03/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing to diagnose allergies	APPROVED	21/03/2013
flunarizine		neurological conditions such as migrane, hemiplegia, cerebral vasculopathy and Moya Moya Syndrome	APPROVED	21/03/2013
Diater DAP Penicillin and Amoxycillin Skin Test Reagents		skin prick testing to diagnose allergies	APPROVED	26/03/2013

Diater DAP Penicillin and Amoxycillin Skin Test Reagents		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing to diagnose allergies	APPROVED	26/03/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	16/05/2013
cholecalciferol 1.25mg (50,000IU)		moderate to severe Vitamin D deficiency	APPROVED	4/04/2013
Indocyanine Green		during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	4/04/2013
Cholecalciferol 1.25 mg (50,000IU)		moderate to severe Vitamin D deficiency	APPROVED	5/04/2013
Diater DAP Penicillin and Amoxycillin Skin Prick Test Reagents		skin prick testing for diagnosis of penicillin and amoxycillin allergies	APPROVED	4/04/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for diagnosis of allergies	APPROVED	4/04/2013

Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnosis of allergies	APPROVED	4/04/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnosis of penicillin allergy	APPROVED	4/04/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	skin prick testing for diagnosing allergies	APPROVED	4/04/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnosing allergies	APPROVED	4/04/2013
Multiple Allergen Skin Prick Test Reagents (Alyostal)	Alyostal	skin prick testing for diagnostic allergy testing	APPROVED	11/04/2013
Cholecalciferol 1.25 mg (50,000IU)		moderate to severe Vitamin D deficiency	APPROVED	20/05/2013
Cholecalciferol 1.25 mg (50,000IU)		moderate to severe Vitamin D deficiency	APPROVED	20/05/2013
cholecalciferol 1.25mg (50,000 IU)	Cal.D.Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	30/05/2013
cholecalciferol 1.25mg (50,000 IU)	Cal.D.Forte, D-3-50	moderate to severe Vitamin D deficiency	APPROVED	20/05/2013
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Streuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Streuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Streuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Streuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection 100,000 IU/mL (D3-Vicotrat)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013
cholecalciferol IM injection 300,000 IU/mL (Vitamine D3 Streuli)		severe Vitamin D deficiency (serum 25-hydroxyvitamin D <30nmol/L)	APPROVED	15/05/2013

[illegible]

[illegible]

Pipothiazine 50mg/mL depot injection (Piportil)	Piportil	for the treatment of psychosis in patients who have experienced problematic side effects with the currently available depot injections	APPROVED	16/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Diater DAP Skin Test Reagents		skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for diagnostic allergy testing	APPROVED	31/05/2013
Multiple Allergen Skin Prick Test Reagents (ALK-Abello)	ALK-Abello	for skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Multiple Allergen Skin Prick Test Reagents (Alyostal)	Alyostal	for skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Diater DAP Skin Prick Test Reagents		for skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
DAP-kit [penicilloyl-poly-L (PPL) and minor determinant mixture (MDM)] and Clavulanic acid		skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for diagnostic allergy testing	APPROVED	28/06/2013
Diater DAP Penicillin and Amoxycillin Skin Test Reagents		skin prick testing for allergy testing	APPROVED	31/05/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for allergy testing	APPROVED	31/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergy testing	APPROVED	31/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergy testing	APPROVED	5/06/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	for skin prick testing to identify allergies	APPROVED	16/05/2013
Penicillin Allergenic Determinants (PAD)		for the diagnosis of penicillin allergic reactions	APPROVED	31/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)		skin prick testing for allergies	APPROVED	5/06/2013
Multiple Allergen Skin Test Reagents (ALK-Abello)		skin prick testing for allergies	APPROVED	5/06/2013
Diater DAP Penicillin and Amoxycillin SkinTest Reagents		skin prick testing for allergies	APPROVED	5/06/2013
urokinase		thrombolysis of occluded vein and prosthetic grafts, arteriovenous dialysis fistulas and during endovascular recanalisation	APPROVED	18/06/2013

Multiple Allergen Skin Test Reagents (ALK-Abello)	ALK Abello	for skin prick testing for allergies	APPROVED	31/05/2013
Multiple Allergen Skin Test Reagents (Alyostal)	Alyostal	for skin prick testing for allergies	APPROVED	31/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Moorefields Phenylephrine 0.6% Intracameral Syringe		for use in Floppy Iris Syndrome in patients undergoing cataract surgery	APPROVED	30/05/2013
Bifidobacterium Bifidum & Lactobacillus Acidophilus (Infloran)	Infloran	preterm neonates born 32 weeks of gestation, for prevention of necrotising enterocolitis (NEC) and mortality	APPROVED	4/06/2013
Indocyanine Green		for use during vitreo-retinal surgery and for intravenous injection to perform ICG angiography	APPROVED	5/06/2013
Diphencyprone (DPCP)	diphenylcyclopropenone	Melanoma recurrent in the skin or metastatic to the skin	APPROVED	4/06/2013